Drug Profile
Research programme: cancer immunotherapeutics - Chinook Therapeutics/Novartis
Alternative Names: CDNs - Chinook Therapeutics; LKZ 145Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator Aduro BioTech
- Developer Chinook Therapeutics; Novartis
- Class Antineoplastics; Small molecules
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 28 Mar 2022 No recent reports of development identified for preclinical development in Cancer in Switzerland (Intratumoural, Injection)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural, Injection)